Filing Flows › Emmaus Life Sciences (EMMA) › Q1 2025
Emmaus Life Sciences (EMMA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Emmaus Life Sciences (EMMA) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -27% from the quarter before. Operating margin was -40.7%, net loss $2.3M (96.8% of revenue).
Emmaus Life Sciences, Q1 2025: revenue $2.4M (-4% year over year), operating margin -40.7%, net loss $2.3M, operating cash flow $279K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -27% | -4% |
| Operating profit | −$980K | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | $279K | -19% | +99% |
What changed
Revenue was $2.4M in Q1 2025, down 4% year over year and down 27% from the previous quarter. Endari was the largest line at 94% of revenue. Endari lost $91K year over year (down 4%), 91% of the total change.
Gross margin was 90.6%, up 0.9 points from a year earlier. Operating costs exceeded revenue by $1.0M, an operating margin of -40.7%. Operating expenses fell 37% while revenue fell 4%. The quarter ended with a net loss of $2.3M, wider than the previous quarter's $1.7M loss. Net interest and other expense of $1.3M was the main reason.
Operating cash flow was $279K (up 99% year over year). Non-cash charges added back $5K of depreciation and $10K of share-based compensation. Working capital and other items added $2.6M.
Questions
What was Emmaus Life Sciences' revenue in the first quarter 2025?
Emmaus Life Sciences (EMMA) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -27% from the quarter before.
Was Emmaus Life Sciences profitable in the first quarter 2025?
Operating loss was $980K (-40.7% of revenue) and net loss $2.3M.